General Information
Revision date
2021-03-17
Product name
Novoeight , Antihemophilic Factor (Recombinant)
Chemical name
Mixture
1.2.2. Uses advised against
None known
supplier name
Novo Nordisk Inc
Manufacturer Name
Novo Nordisk Inc
Emergency telephone
+1-800-727-6500
Icons in SDS
Company Information
company name
Novo Nordisk Inc
GHS Information
Signal word
Not required
Section 2
SECTION 2: Hazards identification
WHMIS 2015 Classification of the chemical Aquesous solution with no specific smell
Signal word
Not required
Hazard statements
Not required
Precautionary statements
Not required
Other hazards which do not result in classification
Pharmaceutical drug, use according to package insert.No special risk if used in accordance with the instructions of the supplier. NovoEight is indicated for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VII or Factor IX.
2.1 Classification of the substance or mixture
Aquesous solution with no specific smell. This material is not classified as hazardous under U.S. OSHA regulations (29CFR 1910.1200) (Hazcom 2012) and Canadian WHMIS regulations (Hazardous Products Regulations) (WHMIS 2015). This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. Your needs may vary depending upon the potential for exposure in your workplace. The precautionary statements, warnings and hazards included herein may not apply in all cases, such as when the product or device is in its final form and being used to treat the approved medical condition(s) while under the care of a licensed medical professional and in accordance with the FDA-approved Prescribing Information. Refer to FDA-approved Prescribing Information for final marketed products with regard to special storage, handling and administration requirements in the clinical setting.
